HAL Allergy is one of the top players in Europe in the field of allergy diagnostics and therapy. In the inter-specialist ranking “Best Pharmaceutical Companies Germany” 2022 in the category “Large individual, medium-sized and international companies”, HAL comes in 7th place. Infectopharm, Gedeon Richter, ALK-Abelló, Exeltis and Procter&Gamble were placed in the first places this year.
HAL Allergy is one of the leading European manufacturers of allergy diagnostics and therapies in the field of specific immunotherapy. The therapies include the treatment of common allergies such as hay fever, dust mite and wasp and bee venom allergies. The company works intensively with its own sales companies, distributors and internationally renowned research institutes to combine knowledge and experience in the best possible way and specialises in the target group of allergy treating physicians from the fields of ENT, dermatology and pulmonology.
HAL: Competence in allergen immunotherapy
HAL Allergy started in 1959 as a small laboratory in Haarlem in the Netherlands. At the request of several local medical practitioners, patient-specific extracts were produced for the treatment of allergies. In the 1970s, HAL Allergy developed into a medium-sized laboratory and expanded into Germany, its most important sales market. Today, HAL Allergy is a subsidiary of the Droege International Group and a top European player in the field of allergen immunotherapy.
The medium-sized company employs around 300 people in branches in 12 European countries. Products are currently distributed in 16 countries. In Germany, 84 employees worked for HAL Allergie GmbH in Düsseldorf in 2019, which achieved a turnover of 17 million euros.
HAL Allergy’s production has been located in a state-of-the-art facility at the Bio Science Park in Leiden, the Netherlands, since 2009.
The company’s research, development and production focus is on the major allergies of the western world. The portfolio includes products for desensitisation against ragweed, tree pollen, mugwort, birch, grasses, mites and various combinations of these allergens, as well as against insect venoms. They are marketed under the brand names PUERTHA, SUBLIVA and VENOMENHAL.
In addition to the development and production of allergy therapeutics, HAL Allergy opened a new business field in 2012 with the contract manufacturer HALIX. HALIX (CDMO) focuses on the production of biotechnological products and is certified for clinical and commercial GMP contract manufacturing of biopharmaceuticals.
For many years now, HAL Allergy has been supporting the LUMC Friends Foundation’s initiative for a child-friendly environment and child-friendly patient care at the Children’s Hospital at Leiden University Medical Center (LUMC). The foundation relies on donations.
